A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
Artemisinin-resistantPlasmodium is an increasing problem. Here, using a medicinal chemistry programme, the authors identify a tetraoxane-based drug candidate that shows no cross-resistance with an artemisinin-resistant strain (PfK13-C580Y) and is efficient in Plasmodiummouse models.
Guardado en:
Ejemplares similares
-
GFAT and PFK genes show contrasting regulation of chitin metabolism in Nilaparvata lugens
por: Cai-Di Xu, et al.
Publicado: (2021) -
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
por: Michael Delves, et al.
Publicado: (2012) -
Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics
por: Sarah Auburn, et al.
Publicado: (2018) -
<italic toggle="yes">Plasmodium falciparum</italic> K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness <italic toggle="yes">In Vitro</italic>
por: Judith Straimer, et al.
Publicado: (2017) -
Silver nanoparticles embedded in zeolite membranes: release of silver ions and mechanism of antibacterial action
por: Nagy A, et al.
Publicado: (2011)